Skip to Content
Merck
All Photos(2)

Key Documents

More Documents

A79809

Sigma-Aldrich

5-Aminosalicylic acid

95%

Synonym(s):

5-AS, 5-Amino-2-hydroxybenzoic acid, Mesalamine

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Linear Formula:
H2NC6H3-2-(OH)CO2H
CAS Number:
89-57-6
Molecular Weight:
153.14
Beilstein:
2090421
EC Number:
201-919-1
MDL number:
MFCD00007877
UNSPSC Code:
12352106
PubChem Substance ID:
24891301
NACRES:
NA.22

Quality Level

200

Assay

95%

form

powder with small lumps

reaction suitability

reaction type: solution phase peptide synthesis

mp

275-280 °C (dec.) (lit.)

application(s)

detection
peptide synthesis

SMILES string

Nc1ccc(O)c(c1)C(O)=O

InChI

1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

InChI key

KBOPZPXVLCULAV-UHFFFAOYSA-N

Gene Information

human ... ALOX5(240) , PPARG(5468) , PTGS1(5742) , PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

5-Aminosalicylic acid is a peroxidase substrate suitable for use in ELISA procedures. This substrate produces a soluble end product that is brown in color and can be read spectrophotometrically at 450 nm. The reaction may be stopped with 3 N NaOH and read at 550 nm.

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 2

Flash Point(F)

536.0 °F

Flash Point(C)

280 °C

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

W Kruis et al.
Alimentary pharmacology & therapeutics, 37(7), 680-690 (2013-02-19)
Robust evidence regarding medical intervention for symptomatic uncomplicated colonic diverticular disease (DD) is sparse. To investigate mesalazine (Salofalk granules) in this setting. In a double-blind, placebo-controlled, multicentre, 6-week trial, patients were randomised to mesalazine 1000 mg three times daily or placebo.
Urpo Nieminen et al.
International journal of cancer, 134(1), 189-196 (2013-06-26)
Patients with long-standing inflammatory bowel disease (IBD) have an increased risk for colorectal carcinoma (CRC). Earlier studies suggest that the severity of inflammation is an independent risk factor for CRC in ulcerative colitis (UC). We investigated the role of histological
Mirjana Rajilić-Stojanović et al.
Inflammatory bowel diseases, 19(3), 481-488 (2013-02-07)
Presence of intestinal microbes is a prerequisite for the development of ulcerative colitis (UC), although deviation of the normal intestinal microbiota composition, dysbiosis, is presumably implicated in the etiology of UC. The fecal microbiota of 30 UC samples obtained from
Christian P Selinger et al.
Inflammatory bowel diseases, 19(10), 2199-2206 (2013-08-01)
Poor adherence frequently impaired the efficacy of therapy to maintain remission from inflammatory bowel diseases (IBD). There is a lack of practical and effective interventions to improve adherence. This study aimed to identify modifiable risk factors, which may yield targets
B Flourié et al.
Alimentary pharmacology & therapeutics, 37(8), 767-775 (2013-03-05)
Aminosalicylates are first-choice treatment for mild-to-moderately active ulcerative colitis (UC); however, multi-dosing regimens are inconvenient. To compare the efficacy and safety of once- (OD) vs. twice- (BD) daily prolonged-release mesalazine (Pentasa, Ferring, Saint-Prex, Switzerland) for active mild-to-moderate UC in a
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service